Psilocybin and ketamine, which is the active ingredient of magic mushrooms, are promising drugs for treating mental disorders. Psychoedelic-assisted therapy clinics are becoming more focused on the patient experience, and not just the use of ketamine or other psychedelic drugs therapies. The therapy is being seen as a part of the overall experience and not the final word. Experts believe that this new direction, which combines digital mental health therapy and psychedelics with other mind-altering substances, can lower the cost of care and improve patient outcomes and protocols.
A report in Axios.com discussed the recent industry conference focusing on the largest psychedelic medicine conference in the U.S., featured speakers ranging from elite psychopharmacologists to the former boxing champion Mike Tyson, who has reinvented himself as an adviser on mental health. Axios stated that the conference’s size is an indication that psychedelic medicine, long considered a fringe science, is now mainstream. He says that there are many promising technologies right now, combining psychedelic treatment with AI and wearables. Wearable devices could provide “digital Phenotyping”, as Cappello Juan Pablo Cappello, CEO and co-founder at NUE Life Health, calls it. This is based on data points such as sleep and activity and will allow for more detailed information than the self-reporting that is used in mental health therapy. According to another insider, “We can assess patients at the beginning, to determine their baseline statistics.” Then, after each experience, we can evaluate them again and see how they are doing. We can also tweak further treatment as necessary. Another source claims that we can lower the cost of ketamine treatment which can run several hundred dollars per infusion. Mind Cure Health Inc., (OTCQX : MCURF), (CSE : MCUR), Cybin Inc., (NYSE: CYBN), (NEO CYBN), Numinus Wellness Inc. [OTCPK : NUMI] (TSX-V : NUMI), Novamind Inc. [OTCQB : NVMDF] (CSE : NM), Mydecine Innovations Group Inc. (“OTCPK : MYCOF”) (NEO : MYCOF)
Axios added: “Studies are increasing evidence that psychedelics such as LSD and Psilocybin, and mind-altering drugs such as MDMA and ketamine can be combined with psychotherapy to combat treatment-resistant anxiety and depression. The FDA approved Esketamine in 2019, a chemical cousin to ketamine. Although it is not known how these drugs work, one theory suggests that they encourage neuroplasticity in anxious or severely depressed brains. The bottom Line: Although psychoedelic therapy is still new, combining it with AI and telemedicine could make it more accessible and provide more detailed data about its effectiveness.
Mind Cure Health Inc. (CSE:MCUR.CNQ), (OTCQX : MCURF). BREAKING NEWS: MINDCURE Announces HIPAA Compliance. This brings iSTRYM closer to commercial deployment in the second quarter of 2022.Mind Cure Health Inc., a pioneer in advanced proprietary technology and research in psychedelics announced today that both the Company and its digital therapy technology, iSTRYM are now comply with the HIPAA (HIPAA) certified under the Company and its digital treatment technology, called iSTRYM, which is iSTRYM, has been certified by the Company and its digital therapeutics technology (iSTRYM) compliance.
MINDCURE’s determination to achieve the highest standards in medical privacy and data protection, iSTRYM being HIPAA compliant reflects that commitment. HIPAA compliance certification will be the next step in the Company’s efforts to have the iSTRYM technology platforms classified as a ‘Software as a Medical Device by the FDA.
Kelsey Ramsden is President & CEO at MINDCURE. He stated that “Receiving HIPAA Compliance is a significant milestone in MINDCURE. This supports our goal to commercially deploy iSTRYM by the second quarter 2022 as well as generating near term revenue from the platform.” MINDCURE will have additional revenue opportunities in the future because iSTRYM is a drug-agnostic platform that we can scale beyond psychedelics.
iSTRYM, a platform for managing mental health practices, empowers healthcare professionals to offer personalized and innovative healing solutions to patients. MINDCURE has positioned iSTRYM as the industry’s distribution network of science-based, evidenced-backed protocols and Artificial Intelligence data system systems.
Geoff Belair is MINDCURE’s Chief Tech Officer. He stated, “We want the company people trust with their minds. And achieving HIPAA was the first step in many to building that trust.” MINDCURE is passionate about data privacy and will ensure that it is a key part of all we offer.
In October, the Company announced that it had reached 10 partner clinics for the iSTRYM program by the end 2021. This includes 20 partnerships with ketamine clinics across nine states in the United States and three Canadian provinces.
Ms. Ramsden said, “Our ability to work with these clinics validates our faith in the iSTRYM Platform and its value for patients and clinicians.” “iSTRYM was established with the goal of changing the paradigm of care and access for psychedelic-assisted therapy. It also aims to reduce the cost and improve patient outcomes. It also provides a distribution network that allows psychedelic companies and distributors to distribute protocols. CONTINUED… To read this and more news for Mind Cure Health, please visit https://www.financialnewsmedia.com/news-mcur/
There have been other recent developments on the markets:
Cybin Inc. (NYSE American: CYBN), (NEO: CYBN), a Biopharmaceutical Company focused on “Psychedelics To Therapeutics(tm),” recentlyannounced it had been granted a Notice Of Allowance by the U.S Patent and Trademark Office (“USPTO”) in connection to patent application No. 17/394,038 is related to CYB004, a Company’s investigational deuterated psychedelic-tryptamine compound for treatment of anxiety disorders. Other forms of deuterated psychoedelic tryptamine are also allowed to be claimed, including certain forms of 5-MeO and DMT. The patent covers composition of matter for CYB004 as a new chemical entity. It is due to expire in 2041.
Doug Drysdale is Chief Executive Officer at Cybin. “The receipt by the USPTO of this Notice of Allowance represents an important milestone in our intellectual property portfolio, progressing psychedelics and therapeutics for the many patients in need. It also strongly demonstrates the Company’s dedication to the development and discovery of differentiated, psychedelic-based compounds to address mental health,” he said. “Once granted, this patent could cover a wide range of claims that support our IP in psychedelic medicines and strengthen our position as a leader in this rapidly changing industry.”
Numinus Wellness Inc. (OTCPK: NUMIF) is a global leader in psychedelics focused mental healthcare. has recently introduced novel, proprietary methods to screen psychedelic mushrooms compounds. This testing was done in-house and will be made available to third-party clients as part of their service offerings. It can also be used for evidence-based discussions with regulators.
Numinus Bioscience is a world leader in psychedelics test development. The Psilocybemushroom extracts, derivatives, and matrices are all being developed. Additionally, required testing such contaminants and residues are performed by the lab, which has also validated active constituents. The Psilocybemushrooms constituent screens includes Psilocin (Psilocin), Baeocystin (Norbaeocystin) and Tryptophan (Norpsilocin) which are the most well-defined alkaloids of Psilocybespecies.
Novamind Inc. (OTCQB, NVMDF), (CSE:NM), a world-renowned mental health company that specializes in psychedelic medicines, has recently announced the opening a new clinic in downtown Salt Lake City (“SLC Clinic”). Novamind offers a range of mental health services. The SLC Clinic, which is led by Dr. Amy de la Garza, focuses on integrative behavioural health for adults with substance abuse disorders (SUD).
SLC Clinic’s outpatient SUD programs offer an alternative to residential treatment and address the complex public health crisis. According to the Centers for Disease Control and Prevention, 93,000 Americans overdosed in 2020, an increase of 30% from the previous year.
Mydecine Innovations Group (OTCPK: MYCOF (NEO: MYCO), is a digital and biotechnology company that aims to improve the treatment of addiction and mental health disorders. recently announced that it had filed a complete patent application for multiple psilocin analogues. This application addresses further precision in shelf stabilization and delivery control of psilocin (psilocybin’s active metabolite), which are crucial for medical use.
Orally administered psilocybin can have a wide range of onset times for patients, making it difficult to standardize protocols or scale treatments. This is why Mydecine has developed a dermal route to administer psilocin. Patent pending permeation enhanced drug by Mydecine provides greater control over the drug and may eliminate undesirable properties such as nausea.
